张仲景抵当汤抗肿瘤作用的研究
|
摘要
卫生部全国第三次死亡原因调查结果显示,恶性肿瘤仅次于脑血管病成为我国城乡居民因病死亡的主要疾病,与之前调查结果相比,恶性肿瘤死亡率比上世纪70年代中期增加了83.1%。现代医学对肿瘤的治疗历经手术、放疗、化疗及生物治疗阶段,近来众多学者又提出肿瘤综合治疗的概念,虽然与过去相比不断得到完善,但在诊断治疗上还存在不少缺陷。如早期肿瘤未转移者；不适于手术、放疗、化疗及患者不愿意西医治疗者；晚期癌痛西药无效者；已经接受手术、放疗、化疗需要中医减轻并发症及辅助治疗的患者等,这些缺陷正是现代医学亟待研究的课题。而传统中医药在某些方面却有着一定的优势,如何充分发挥这些优势,为恶性肿瘤的治疗找到一条新的有效的途径,积极研究中医药抗肿瘤的组方并探索其配伍规律,通过在实验研究的基础上改良或创制新的有效处方为广大肿瘤患者提供中医药服务,正是我们研究的出发点和目的之所在。
恶性肿瘤在古代中医文献中早有很多记载,属于癥瘕积聚范畴,其产生的病因病机比较复杂,临床表现多有瘀热之证,瘀热作为一种新的致病因素越来越受到业界的重视,查阅文献资料发现,瘀热互结是恶性肿瘤的一个重要病机。现代医学也证实血瘀是恶性肿瘤形成发展的主要病理机制,而且出现在恶性肿瘤的生长期、浸润期和转移期各个阶段,肿瘤患者同时存在着血液粘滞度增高、血液流变学异常及微循环障碍等病理性改变。活血化瘀祛邪成为肿瘤治疗中广泛采用的重要手段之一,同时在疾病的不同阶段兼顾扶正补虚。抵当汤是张仲景活血化瘀的经典方,主要用于太阳阳明蓄血证及妇人经不不利下之闭经,由水蛭、虻虫、大黄、桃仁四味药物组成,具有破血逐瘀,软坚散结之功,文献报道抵当汤有抗肿瘤作用。根据中医理论的指导和对历代活血化瘀方配伍规律的研究,我们在抵当汤原方基础上分别加上行气药柴胡、温经药桂枝和补气药黄芪,再进行实验比较研究。
本文观察了抵当汤对疼痛炎症的影响；观察了抵当汤及其加味方对人乳腺癌MCF-7细胞,人结肠癌HCT-28细胞,人肝癌HepG-2细胞的影响；研究了其对S180荷瘤小鼠的肿瘤生长、机体免疫状态、肿瘤局部及全身血液循环、外周血液中的白细胞介素-8(IL-8)、肿瘤坏死因子-α(TNF-α)的影响。以期通过系列实验明确抵当汤及其加味方的作用,并在此基础上分析抵当汤及其加味方的组成,在中医理论的指导下,探求其组方的原则和规律。
1.抵当汤镇痛抗炎作用：以耳肿法和醋酸扭体法观察抵当汤对炎症疼痛的影响,结果表明抵当汤低、中、高剂量组均可明显对抗二甲苯所致小鼠耳肿胀和醋酸引起小鼠扭体反应,且存在一定的量效关系；
2.抵当汤体外抑制肿瘤细胞的生长：采用MTT法观察抵当汤对人MCF-7、HCT-28、HepG-2增殖的影响,结果表明抵当汤对人MCF-7、HCT-28、HepG-2细胞均有一定的杀伤能力,其中人MCF-7和HepG-2细胞对其更为敏感；
3.抵当汤对S180荷瘤小鼠的抑瘤作用：以S180荷瘤小鼠为模型,观察抵当汤对瘤重、免疫器官脏器指数和白细胞计数的影响,结果表明抵当汤中、高剂量组可明显抑制S180荷瘤小鼠的瘤重、提高S180荷瘤小鼠脾指数和胸腺指数及外周血白细胞数量；
4.抵当汤及其加味方对体外肿瘤细胞生长的影响：采用MTT法观察抵当汤及各加味汤对人MCF-7、HCT-28、HepG-2生长的影响并计算IC50,结果表明各加味汤均能抑制癌细胞的增殖,且较抵当汤明显,抵当汤加柴胡组优于抵当汤加桂枝组而又优于抵当汤加黄芪组；
5.抵当汤加味方对S180荷瘤小鼠的抑瘤影响：以S180荷瘤小鼠为模型,观察各方对抑瘤率、机体免疫状况、血液指标、肿瘤局部血管及血液循环及外周血白细胞介素-8(IL-8)、肿瘤坏死因子-α(TNF-α)的影响,结果表明抵当汤组、抵当汤加柴胡组、抵当汤加桂枝组均可明显抑制肿瘤的生长,抵当汤加用柴胡和桂枝后,抑瘤率有进一步增加,其中加用柴胡组与单用抵当汤相比抑瘤率有明显增加,提示加用柴胡和桂枝可加强抵当汤的抑瘤效应。抵当汤及分别加入柴胡、桂枝、黄芪三个加味方都有促进外周血液循环的作用,其中以抵当汤加桂枝组可明显提高小鼠耳廓微循环；抵当汤及分别加入柴胡、桂枝、黄芪三个加味方都有抑制S180荷瘤小鼠肿瘤局部微循环,其中以抵当汤加黄芪组作用最为明显。抵当汤及加味方对外周血白细胞介素-8(IL-8)和肿瘤坏死因子-α(TNF-α)与对照比有差异,其中加入柴胡组有明显差异。
综上所述,1、抵当汤及其加味方有抗肿瘤作用,而分别加入柴胡、桂枝的加味方比加入黄芪和原抵当汤的作用显著,其中加入柴胡组有明显差异；2、抵当汤及加味方能促进外周血液循环而抑制肿瘤局部血液循环；3、抵当汤对体外肿瘤细胞有活性作用,而加入柴胡、桂枝、黄芪的三个加味方活性作用均大于原方抵当汤活性作用,其中加入柴胡、桂枝的活性作用相比黄芪又更为明显,抵当汤及加味方对人MCF-7细胞的生长抑制最为明显。本文通过对抵当汤及加味方组成研究将有助于对中药复方配伍规律科学性的理解,进一步拓宽仲景活血化瘀组方思路,找出活血化瘀配伍的内在规律,为我们组成新的方剂提供实验依据。
According to Ministry of Health's third time survey results on the cause of death:after cerebrovascular disease, malignant cancer is the second main disease causing death in China's urban and rural area; and compared to the survey on the death rate caused by the malignant tumor in the middle of 1970s, it is increased by 83.1%today. After surgery, radiotherapy, chemotherapy and biological treatment stage, many scholars have recently proposed the concept of comprehensive cancer treatment, which has been refined than in the past, but there are still many deficiencies on the diagnosis and treatment. Such as patient of early cancer without metastasis; patient not suit to surgery, radiotherapy, chemotherapy or do not accept the Western Medicine treatment; medicine is ineffective in advanced cancer patient; patient who has already receive surgery, radiotherapy and chemotherapy needs to receive Traditional Chinese Medicine as adjunctive therapy or reducing the complications, etc.. All these defects are urgent problems need to be resolved by the modern medicine. The traditional Chinese Medicine in some ways has a certain advantage. Our research aims are:How to fully exploit these advantages to find a new effective way for the treatment of the tumor, research Traditional Chinese Medicine prescriptions on tumor and explore the law of compatibility, and based on experimental study to improve or create new effective prescription for the majority of cancer patients
Malignant tumor has been recorded numerously in the ancient literature, which belonged to the sphere of aggregation-accumulation. Its etiological factor and pathogenesis is complicated, and mostly clinical manifestation is heat stasis, which becomes to a new disease factor and more and more highlighted by the medical area. By the literature information, stasis and heat complex is an important pathogenesis inviting the malignant tumor. Modern medicine also proved that blood stasis is a main pathogenesis to cause malignant tumor, and appeared in the growth period, infiltrated period and extension period. The patient of tumor always goes through the pathologic changes like increasing of blood viscosity, abnormality of blood rheological characteristic and disorder of microcirculation. Activate blood, dissipate stasis and eliminate the pathogenic factors are the important methods applied universally in the treatment of tumor, meantime in different phases reinforce the healthy Qi and tonify the deficiency are necessary. Di dang decoction is the classic prescription to activate blood and dissipate stasis created by Zhang Zhong-jing, which is usually applied in great yang blood-retention syndrome or yang brightness blood-retention pattern and aggregation-accumulation of women. Di dang decoction is composed by leech, gadfly, pieplant and persicae, with the power to break blood and expel stasis, and soften hardness and dissipate binds. Besides, it is said that Di dang decoction has the function of anti-tumor. Under the guidance of TCM theory, and the research on compatibility of prescription of blood activation and stasis dissipation, we added bupleuri to move Qi, Gui-zhi to warm meridians and collaterals, and astragali to tonify Qi, and then make comparison research through the experiment.
We observed the influence of Di dang decoction on the pain and inflammation, observed the influence of Di dang decoction and its modified formula to breast cancer MCF-7 cell, colon cancer HCT-28 cell, and liver cancer HepG-2 cell; observed the influence of decoction to S180 tumor-bearing mice's tumor growth, organism immunity, region of tumor and blood circulation all over the whole body, periphery blood interleukin-8, tumor necrosis factor-α. Though the series of experiments, we would like to identify the function of Di dang decoction and its modified formula, then under the direction of TCM, we will give the further analysis to its principle of composition.
The anti-inflammatory analgesic function of Di dang decoction:Through the ear swelling method and acetic acid writhing method to observe the impact of Di dang decoction on inflammatory pain, results showed that Di dang decoction in low, middle or high dose group could significantly against the ear swelling and acetic acid writhing response induced by xylene in mice, and there was a certain dose-effect relationship;
Extraorgan inhibition of growth of tumor cells of Di dang decoction:MTT was used to observe the influence of Di dang decoction on MCF-7, HCT-28, HepG-2 proliferation in human body, the results showed that Di dang decoction had the certain destruction ability on MCF-7, HCT-28, HepG-2 cells, MCF-7 and HepG-2 cells of which were more sensitive to Di dang decoction;
Tumor inhibition on the S180 tumor-bearing mice of Di dang decoction:S180 tumor-bearing mice as a model to observe the effect of Di dang decoction on tumor weight, organ index of immune organs and leukocyte counts, the results showed that when Di dang decoction in middle or high dose group, the tumor weight of S180 tumor-bearing mice was significantly inhibited, and index of spleen and thymus are obviously improved, as well as the number of peripheral blood leucocyte.
Impact of Di dang decoction and its modified formula on the growth of extraorgan tumor cells growth:MTT was applied to observe the impact on MCF-7、HCT-28、HepG-2 cells growth and calculate IC50, we found that Di dang decoctions added with different herb medicines could inhibit the proliferation of cancer cells, the effect being superior to Di dang decoction itself. In three different types of its modified formula, bupleuri-added decoction was superior than Gui zhi-added decoction, astragali-added decoction was the last one of three;
Tumor inhibition of Di dang decoction's modified formula on S180 tumor-bearing mice:S180 tumor-bearing mice as a model to observe the effect on the rate of inhibition of tumor, the organism immunity situation, blood index, the regional blood vessel of tumor, blood circulation and IL-8, and TNF-a, and the results were Di dang decoction, Di dang decoction plus bupleuri and Di dang decoction plus Guizhi inhibited the growth of tumor significantly; the function of inhibition of tumor growth enhanced when Di dang decoction plus bupleuri or Guizi. Separately, the function of tumor growth inhibition of Di dang decoction plus bupleuri was much more significant than Di dang decoction itself only, implying that the tumor inhibition effect was enhanced when the Di dang decoction plus bupleuri or Guizi. Di dang decoction and its prescrption separately added bupleuri, Guizhi or astragali could stimulate the peripheral blood circulation, of which Guizhi-plus group could improve auricle microcirculation of mice notably. Di dang decoction and Di dang decoction separately added bupleuri, Guizi or astragali could inhibit the regional blood circulation around the tumor of S180 tumor-bearing mice, of which astragali-plus prescription was the most effective one. The function on IL-8 and TNF-a of Di dang decoction and its modified formula distinguished from control group, especially the bupleuri-plus group.
In summary:1.Di dang decoction and its modified formula has the anti-tumor function, and anti-tumor function in Bupleurum-modified and Guizhi-modified prescription are much more effective than astragalus group and original decoction, Bupleurum group was significantly different; 2. Di dang decoction and its modified prescription can promote peripheral blood circulation and inhibit local blood circulation around tumor;3. Di dang decoction has the activity function to extraorgan tumor cells. While adding Bupleurum, Guizi and Astragalus, the activity function of these improved decoctions are greater than the original decoction, in addition, Bupleurum and Guizhi group are more obvious than Astragalus group. Didangtang decoction and its improved prescription inhibit the growth of breast cancer MCF-7 significantly. The research on the composition of Di dang decoction and its improved prescription will contribute to the scientific understanding to the TCM compound compatibility law; find out the inherent rule of activating blood and dissipate stasis compatibility, which provide experimental evidence as we form a new prescription, to develop Zhongjing's recipe idea of activating blood and dissipate stasis.
恶性肿瘤在古代中医文献中早有很多记载,属于癥瘕积聚范畴,其产生的病因病机比较复杂,临床表现多有瘀热之证,瘀热作为一种新的致病因素越来越受到业界的重视,查阅文献资料发现,瘀热互结是恶性肿瘤的一个重要病机。现代医学也证实血瘀是恶性肿瘤形成发展的主要病理机制,而且出现在恶性肿瘤的生长期、浸润期和转移期各个阶段,肿瘤患者同时存在着血液粘滞度增高、血液流变学异常及微循环障碍等病理性改变。活血化瘀祛邪成为肿瘤治疗中广泛采用的重要手段之一,同时在疾病的不同阶段兼顾扶正补虚。抵当汤是张仲景活血化瘀的经典方,主要用于太阳阳明蓄血证及妇人经不不利下之闭经,由水蛭、虻虫、大黄、桃仁四味药物组成,具有破血逐瘀,软坚散结之功,文献报道抵当汤有抗肿瘤作用。根据中医理论的指导和对历代活血化瘀方配伍规律的研究,我们在抵当汤原方基础上分别加上行气药柴胡、温经药桂枝和补气药黄芪,再进行实验比较研究。
本文观察了抵当汤对疼痛炎症的影响；观察了抵当汤及其加味方对人乳腺癌MCF-7细胞,人结肠癌HCT-28细胞,人肝癌HepG-2细胞的影响；研究了其对S180荷瘤小鼠的肿瘤生长、机体免疫状态、肿瘤局部及全身血液循环、外周血液中的白细胞介素-8(IL-8)、肿瘤坏死因子-α(TNF-α)的影响。以期通过系列实验明确抵当汤及其加味方的作用,并在此基础上分析抵当汤及其加味方的组成,在中医理论的指导下,探求其组方的原则和规律。
1.抵当汤镇痛抗炎作用：以耳肿法和醋酸扭体法观察抵当汤对炎症疼痛的影响,结果表明抵当汤低、中、高剂量组均可明显对抗二甲苯所致小鼠耳肿胀和醋酸引起小鼠扭体反应,且存在一定的量效关系；
2.抵当汤体外抑制肿瘤细胞的生长：采用MTT法观察抵当汤对人MCF-7、HCT-28、HepG-2增殖的影响,结果表明抵当汤对人MCF-7、HCT-28、HepG-2细胞均有一定的杀伤能力,其中人MCF-7和HepG-2细胞对其更为敏感；
3.抵当汤对S180荷瘤小鼠的抑瘤作用：以S180荷瘤小鼠为模型,观察抵当汤对瘤重、免疫器官脏器指数和白细胞计数的影响,结果表明抵当汤中、高剂量组可明显抑制S180荷瘤小鼠的瘤重、提高S180荷瘤小鼠脾指数和胸腺指数及外周血白细胞数量；
4.抵当汤及其加味方对体外肿瘤细胞生长的影响：采用MTT法观察抵当汤及各加味汤对人MCF-7、HCT-28、HepG-2生长的影响并计算IC50,结果表明各加味汤均能抑制癌细胞的增殖,且较抵当汤明显,抵当汤加柴胡组优于抵当汤加桂枝组而又优于抵当汤加黄芪组；
5.抵当汤加味方对S180荷瘤小鼠的抑瘤影响：以S180荷瘤小鼠为模型,观察各方对抑瘤率、机体免疫状况、血液指标、肿瘤局部血管及血液循环及外周血白细胞介素-8(IL-8)、肿瘤坏死因子-α(TNF-α)的影响,结果表明抵当汤组、抵当汤加柴胡组、抵当汤加桂枝组均可明显抑制肿瘤的生长,抵当汤加用柴胡和桂枝后,抑瘤率有进一步增加,其中加用柴胡组与单用抵当汤相比抑瘤率有明显增加,提示加用柴胡和桂枝可加强抵当汤的抑瘤效应。抵当汤及分别加入柴胡、桂枝、黄芪三个加味方都有促进外周血液循环的作用,其中以抵当汤加桂枝组可明显提高小鼠耳廓微循环；抵当汤及分别加入柴胡、桂枝、黄芪三个加味方都有抑制S180荷瘤小鼠肿瘤局部微循环,其中以抵当汤加黄芪组作用最为明显。抵当汤及加味方对外周血白细胞介素-8(IL-8)和肿瘤坏死因子-α(TNF-α)与对照比有差异,其中加入柴胡组有明显差异。
综上所述,1、抵当汤及其加味方有抗肿瘤作用,而分别加入柴胡、桂枝的加味方比加入黄芪和原抵当汤的作用显著,其中加入柴胡组有明显差异；2、抵当汤及加味方能促进外周血液循环而抑制肿瘤局部血液循环；3、抵当汤对体外肿瘤细胞有活性作用,而加入柴胡、桂枝、黄芪的三个加味方活性作用均大于原方抵当汤活性作用,其中加入柴胡、桂枝的活性作用相比黄芪又更为明显,抵当汤及加味方对人MCF-7细胞的生长抑制最为明显。本文通过对抵当汤及加味方组成研究将有助于对中药复方配伍规律科学性的理解,进一步拓宽仲景活血化瘀组方思路,找出活血化瘀配伍的内在规律,为我们组成新的方剂提供实验依据。
According to Ministry of Health's third time survey results on the cause of death:after cerebrovascular disease, malignant cancer is the second main disease causing death in China's urban and rural area; and compared to the survey on the death rate caused by the malignant tumor in the middle of 1970s, it is increased by 83.1%today. After surgery, radiotherapy, chemotherapy and biological treatment stage, many scholars have recently proposed the concept of comprehensive cancer treatment, which has been refined than in the past, but there are still many deficiencies on the diagnosis and treatment. Such as patient of early cancer without metastasis; patient not suit to surgery, radiotherapy, chemotherapy or do not accept the Western Medicine treatment; medicine is ineffective in advanced cancer patient; patient who has already receive surgery, radiotherapy and chemotherapy needs to receive Traditional Chinese Medicine as adjunctive therapy or reducing the complications, etc.. All these defects are urgent problems need to be resolved by the modern medicine. The traditional Chinese Medicine in some ways has a certain advantage. Our research aims are:How to fully exploit these advantages to find a new effective way for the treatment of the tumor, research Traditional Chinese Medicine prescriptions on tumor and explore the law of compatibility, and based on experimental study to improve or create new effective prescription for the majority of cancer patients
Malignant tumor has been recorded numerously in the ancient literature, which belonged to the sphere of aggregation-accumulation. Its etiological factor and pathogenesis is complicated, and mostly clinical manifestation is heat stasis, which becomes to a new disease factor and more and more highlighted by the medical area. By the literature information, stasis and heat complex is an important pathogenesis inviting the malignant tumor. Modern medicine also proved that blood stasis is a main pathogenesis to cause malignant tumor, and appeared in the growth period, infiltrated period and extension period. The patient of tumor always goes through the pathologic changes like increasing of blood viscosity, abnormality of blood rheological characteristic and disorder of microcirculation. Activate blood, dissipate stasis and eliminate the pathogenic factors are the important methods applied universally in the treatment of tumor, meantime in different phases reinforce the healthy Qi and tonify the deficiency are necessary. Di dang decoction is the classic prescription to activate blood and dissipate stasis created by Zhang Zhong-jing, which is usually applied in great yang blood-retention syndrome or yang brightness blood-retention pattern and aggregation-accumulation of women. Di dang decoction is composed by leech, gadfly, pieplant and persicae, with the power to break blood and expel stasis, and soften hardness and dissipate binds. Besides, it is said that Di dang decoction has the function of anti-tumor. Under the guidance of TCM theory, and the research on compatibility of prescription of blood activation and stasis dissipation, we added bupleuri to move Qi, Gui-zhi to warm meridians and collaterals, and astragali to tonify Qi, and then make comparison research through the experiment.
We observed the influence of Di dang decoction on the pain and inflammation, observed the influence of Di dang decoction and its modified formula to breast cancer MCF-7 cell, colon cancer HCT-28 cell, and liver cancer HepG-2 cell; observed the influence of decoction to S180 tumor-bearing mice's tumor growth, organism immunity, region of tumor and blood circulation all over the whole body, periphery blood interleukin-8, tumor necrosis factor-α. Though the series of experiments, we would like to identify the function of Di dang decoction and its modified formula, then under the direction of TCM, we will give the further analysis to its principle of composition.
The anti-inflammatory analgesic function of Di dang decoction:Through the ear swelling method and acetic acid writhing method to observe the impact of Di dang decoction on inflammatory pain, results showed that Di dang decoction in low, middle or high dose group could significantly against the ear swelling and acetic acid writhing response induced by xylene in mice, and there was a certain dose-effect relationship;
Extraorgan inhibition of growth of tumor cells of Di dang decoction:MTT was used to observe the influence of Di dang decoction on MCF-7, HCT-28, HepG-2 proliferation in human body, the results showed that Di dang decoction had the certain destruction ability on MCF-7, HCT-28, HepG-2 cells, MCF-7 and HepG-2 cells of which were more sensitive to Di dang decoction;
Tumor inhibition on the S180 tumor-bearing mice of Di dang decoction:S180 tumor-bearing mice as a model to observe the effect of Di dang decoction on tumor weight, organ index of immune organs and leukocyte counts, the results showed that when Di dang decoction in middle or high dose group, the tumor weight of S180 tumor-bearing mice was significantly inhibited, and index of spleen and thymus are obviously improved, as well as the number of peripheral blood leucocyte.
Impact of Di dang decoction and its modified formula on the growth of extraorgan tumor cells growth:MTT was applied to observe the impact on MCF-7、HCT-28、HepG-2 cells growth and calculate IC50, we found that Di dang decoctions added with different herb medicines could inhibit the proliferation of cancer cells, the effect being superior to Di dang decoction itself. In three different types of its modified formula, bupleuri-added decoction was superior than Gui zhi-added decoction, astragali-added decoction was the last one of three;
Tumor inhibition of Di dang decoction's modified formula on S180 tumor-bearing mice:S180 tumor-bearing mice as a model to observe the effect on the rate of inhibition of tumor, the organism immunity situation, blood index, the regional blood vessel of tumor, blood circulation and IL-8, and TNF-a, and the results were Di dang decoction, Di dang decoction plus bupleuri and Di dang decoction plus Guizhi inhibited the growth of tumor significantly; the function of inhibition of tumor growth enhanced when Di dang decoction plus bupleuri or Guizi. Separately, the function of tumor growth inhibition of Di dang decoction plus bupleuri was much more significant than Di dang decoction itself only, implying that the tumor inhibition effect was enhanced when the Di dang decoction plus bupleuri or Guizi. Di dang decoction and its prescrption separately added bupleuri, Guizhi or astragali could stimulate the peripheral blood circulation, of which Guizhi-plus group could improve auricle microcirculation of mice notably. Di dang decoction and Di dang decoction separately added bupleuri, Guizi or astragali could inhibit the regional blood circulation around the tumor of S180 tumor-bearing mice, of which astragali-plus prescription was the most effective one. The function on IL-8 and TNF-a of Di dang decoction and its modified formula distinguished from control group, especially the bupleuri-plus group.
In summary:1.Di dang decoction and its modified formula has the anti-tumor function, and anti-tumor function in Bupleurum-modified and Guizhi-modified prescription are much more effective than astragalus group and original decoction, Bupleurum group was significantly different; 2. Di dang decoction and its modified prescription can promote peripheral blood circulation and inhibit local blood circulation around tumor;3. Di dang decoction has the activity function to extraorgan tumor cells. While adding Bupleurum, Guizi and Astragalus, the activity function of these improved decoctions are greater than the original decoction, in addition, Bupleurum and Guizhi group are more obvious than Astragalus group. Didangtang decoction and its improved prescription inhibit the growth of breast cancer MCF-7 significantly. The research on the composition of Di dang decoction and its improved prescription will contribute to the scientific understanding to the TCM compound compatibility law; find out the inherent rule of activating blood and dissipate stasis compatibility, which provide experimental evidence as we form a new prescription, to develop Zhongjing's recipe idea of activating blood and dissipate stasis.
引文
[1]李连弟,鲁凤珠,张思维,等.中国恶性肿瘤死亡率20年变化趋势和近期预测分析.中华肿瘤杂志,1997,19(1)：3.
[2]闰洪飞.谈浅中医肿瘤病名的命名,中医文献杂志,2004, (4)：34
[3]郭炜,赵泽贞,单保恩,等.六种中草药的抗突变及抗肿瘤活性的实验报告.癌变.畸变.突变,2002,14(2)：95-97.
[4]赵泽贞,魏丽珍.22种可食性中药材的抗突变和致突变同步快速试验,癌变、畸变、突变,2002,12(2)：8789
[5]施汀兰,杨雪,冉长清.中药抗肿瘤作用研究概况,重庆中草药研究,2008(2)：32
[6]郑炜望,华海清.中药诱导肝癌细胞凋亡的研究进展.世界华人消化杂志2009；17(28)：2915-2918
[7]殳迎春,范平国.动物类中药在抗肿瘤方面的应用,现代医药卫生2005,21(20)：2820
[8]汪海英.抗肿瘤中药的研究现状,青海医学院学报,2008,29(4)：278
[9]郭娟娟,潘祥林,冯长伟,等.冬凌草甲素诱导多药耐药细胞系K562／A02凋亡、逆转耐药性的研究,安徽中医学院学报,2000,19(3)：34.
[10]马龙,徐臻荣,付德润,等.新疆红景天水提取液抗诱变作用的实验研究[J].现代康复,1998；2(1)：58-59.
[11]韩玉英,丰平,文朝阳.抗癌中草药研究进展,北京中医杂志,2003,22(2)：45
[12]肖秀玲,贾海波.中药有效成分抗肿瘤作用研究进展[J].内蒙古中医药,2007(5)：47.
[13]江石湖,徐水平,谭继宏,等.羟基喜树碱诱导胃癌细胞凋亡的实验研究.中华消化杂志,1999,19(1)：19-20.
[14]徐令,廖清奎,罗春化,等.Fas基因在高三尖杉酯碱诱导HL-60细胞凋亡中的作用. 中华儿科杂志,1998,10(10)：607-609.
[15]周振华,宋振明,于尔辛,等.中药诱导肿瘤细胞凋亡的研究进展,国外医学.中医中药分册,1998,(3)：3.
[16]杨小萍,潘启超,谢冰芬,等.骆驼蓬总碱抗肿瘤及其协同抗瘤作用[J].中草药,1998,29(9)：609—611.
[17]黄园,庄镇华,侯世祥,等.草乌抗肝癌靶向制剂有效部位的浸出、纯化与确认[J].中国中药杂志,1997,22(11)：667—671.
[18]咸丽娜,钱士辉,抗癌中药研究进展,中国野生植物资源,2009,28(4)：1
[19]许继平,周振鹤,杨锋,等.六味地黄液抗肿瘤化疗的毒副作用研究.中国中西医结合杂志,1992,15(12)：734
[20]邢雪梅,邢聪,邢磊,等.抗癌中药的生物治疗效应研究近况.中医杂志,1994,35(3)：177.
[21]贺新怀,席孝贤.试论中药诱导肿瘤细胞凋亡的机制[J].陕西中医学院学报,1999,22(5)： 62.
[22]王明艳,吴海涛,赵鸣芳,等.4种方药对环磷酰胺诱发的SCE的抑制作用[J].中成药药,2000,22(3)：212-214
[23]李震,李军山,李哲,等.清热解毒方对肿瘤小鼠红细胞膜流动性及血浆环核苷酸水平的影响,山东生物医学工程,2001,20(3)：8
[24]陈培丰.清热解毒法诱导肿瘤细胞凋亡的研究,浙江中医学院学报2003,27(1)：12
[25]原志庆.6种中草药阻断食管上皮癌变的实验研究.河南肿瘤学杂志,1998,11(5)：396-397.
[26]金红,吴湘玮,潘博,等.鼻咽复方配合放疗治疗鼻咽癌260例疗效观察.湖南中医杂志,1997,13(3)：20.
[27]陈英.益气养血、清热解毒治疗乳癌术后41例,浙江中医学院学报,1999,23(6)：30.
[28]贾英杰,田菲,陈军,等.解毒祛瘀法对肿瘤血管生成影响的实验研究[J].天津中医药,2004,21(6)：467-469.
[29]曹科,潘艳芳,陈佩禅,等.抵当汤对小鼠肿瘤转移及酪氨酸激酶受体信号传导系统EGFR的影响[J].中医药学刊,2004,22(11)：2026.
[30]吴焱森,谢则平.抵当汤对荷瘤小鼠免疫功能影响的实验研究[J].湖北省卫生职工医学院学报,2001,14(2)；6.
[31]许洪霞,王雅贤,许艳霞.桃核承气汤对荷瘤小鼠影响的实验研究[J].中医药信息,2006,23(1)：52.
[32]王学良,杨运高,王程.抵当汤抑制肿瘤转移的实验研究,湖南中医杂志2004,(20)3：69
[33]韩彦龙.桂枝茯苓丸抗肿瘤作用的实验研究,牡丹江医学院学报,2003,24(6)：9
[34]陈泽雄,陈雯,彭俊生,等.中药复方抗癌方抑制人结肠癌细胞株端粒酶活性.中国胃肠外科杂志,1999,2(2)：117-118.
[35]邬晓东.自拟鳖陈汤治疗恶性肿瘤验案3则,成都中医药大学学报,2002,25(2)：46-47.
[36]夏亲华.中药扶正培本、化瘀解毒配合腹腔化疗治疗晚期卵巢癌.安徽中医临床杂志,1999,11(1)：5-6.
[37]杨振江,赵霞.髓清丸对裸小鼠黑色素瘤B16自发性肺转移影响的研究[J].成都中医药大学学报,2004,27(2)：30-32.
[38]李学汤,王永泉,傅乃武.几种活血化瘀药物对小鼠肝癌细胞形成肺转移影响的初步实验观察[J].中医杂志,1980,21(8)：75.
[39]傅乃武,范贤俊,王永泉,等.丹参对实验肿瘤生长和转移的影响及其作用原理的初步探讨[J].中华肿瘤杂志,1981,3(3)：165.
[40]黄兆明,何小琴.丹参、赤芍、莪术对小鼠Lewis肺癌血管生成的影响[J].实用中西医结合临床,2006,6(1)：74-75.
[41]毕良研,杨秀婷,姜家康,等.活血化瘀法不宜应用于恶性肿瘤的临床治疗[J].中医药学报,1997(2)：
[42]徐德成,张培宇.活血化瘀强度与气血双亏型胃癌转移率相关性机制探讨[J]中医杂志,1998,39(3)：156.
[43]夏跃胜,王建华,刘星,等.放射疗法联合应用活血与扶正活血中药治疗鼻咽癌的对比研究[J].中国中西医结合耳鼻咽喉科杂志,2002,10(2)：72.
[44]陈刚,徐晓玉,严鹏科,等.川芎嗪和丹参对小鼠Lewis肺癌生长的抑制作用与抑制血管生成的关系[J].中草药,2004,35(3)：296-299.
[45]刘明章,黄胎核,肖伟瑶.丹参酮ⅡA磺酸钠对Lewis肺癌无促进生长与转移作用[J].中国药理学报,1991,12(6)：534.
[46]张海林,聂克.活血化瘀药对恶性肿瘤影响研究进展,山东中医药大学学报,2009,32(2)：169
[47]周仲瑛.瘀热相搏证的系列研究(一).天津中医药大学学报,2008,27(3)：151
[48]周仲瑛.瘀热相搏证的系列研究(二).天津中医药大学学报,2008,27(4)：237
[49]张静,吴正.凉血散淤抗肿瘤研究进展,时珍国医国药2008,(19)4：1017
[50]陈宁.中晚期原发性肝癌中药应用规律[J].陕西中医,1995,16(2)：87.
[51]吴勉华,过伟峰,周学平,等.研究周仲瑛“瘀热”学说的思路与方法,中华中医药杂志,2009,24(10)：1319
[52]吴贻谷,宋立人.《中华本草》.上海科学技术出版社,1999
[53]刘敏,刘振权,李宇航,等.仲景方中水蛭用药剂量研究,中国现代药物应用,2009,21(3)：77
[54]活血祛瘀剂选药配伍规律纵横谈,2002年山东中医药大学硕士研究生论文
[55]罗眈,陈名斌,彭睿,等.活血化瘀配伍方法探析,四川中医,2008,26(11)：105
[56]姜波,艾华.抵当汤化裁方对荷瘤小鼠抑瘤作用及对T淋巴细胞亚群的影响,吉林中医药2008,(28)2：147
[57]吴焱森,抵当汤对荷瘤小鼠免疫功能影响的实验研究,湖北省卫生职工医学院学报2001,(14)2：6
[58]杨运高,王程,王学良,等.红细胞免疫低下与肿瘤转移及活血化瘀方药的调节,湖南中医杂志,2004,20(6)：52
[59]王学良,杨运高,王程.抵当汤抑制肿瘤转移的实验研究,2004,20(3)：69
[60]王程,杨运高,王学良.活血化瘀经典方剂对小鼠大肠癌肝转移模型端粒酶及p53、C-erbB-2、Bcl-2基因表达的影响[J].第一军医大学学报,2004,24(7)：11.
[61]刘京生,苗智慧,董力,等.水蛭抗肿瘤作用的实验研究[J].时珍国医国药,2001,12(10)：884-885
[62]谢艳华,王四旺,崔翰明.水蛭对正常及血瘀模型大鼠血液流变的影响[J].第四军医大学学报,1996,17(2)：52.
[63]黄国钧,王选明,毛兴云,等.回生口服液抗肿瘤作用实验研究.中成药,1998,20(10)：37～39.
[64]难波恒雄.生药学杂志(日),1982,36(4)：289
[65]沈映君.中药药理学[M].上海：上海科学技术出版社,1997
[66]万宗明,孙文军,陈虹.大黄酸抗肿瘤作用的研究进展.武警医学杂志,2006,17(8)：611.
[67]孙丽霞,任金荣,单保恩,等.大黄制剂对小鼠的急性毒性和自然免疫调节作用.癌变·畸变·突变,2006,18(1)：35.
[68]刘英,张伟刚,王雅贤,等.炒桃仁总蛋白对小鼠B细胞功能影响的实验研究.中医药学报,2001,29(2)：55.
[69]吕跃山,王雅贤,运晨霞,等.桃仁总蛋白对荷瘤鼠IL-2、IL-4水平的影响,中医药信息,2004,21(4)：60
[70]杨雁,陈敏珠.黄芪总苷对肝癌细胞凋亡及wtp53基因表达的影响.中国药理学通报2001； 17：447-451
[71]金宏勋.黄芪水煎液对环磷酞胺抗肿瘤活性与毒性的影响.中药材,1995,18(7)：356.
[72]马占好.黄芪多糖对小鼠提内六种细胞系瘤株抑瘤作用的实验研究[J].中医药学报,1996(4)：55-56.
[73]季宇彬.抗癌中药药理与应用.黑龙江：黑龙江科学技术出版社,2004,2：1075.
[74]黄敬群,罗晓星,王四旺,等.桂皮醛抗肿瘤活性及对S180荷瘤小鼠免疫功能的影 响[J].中国临床康复.2006,10(11)：107-110.
[75]和水祥,罗金燕,赵刚,等.柴胡皂苷对肝癌SMMC-7721细胞环氧合酶-2表达的影响[J].中华肝脏病杂志,2006,14(9)：712-714.
[76]韩玉英,丰平,文朝阳.抗癌中草药研究进展[J].北京中医杂志,2003,22(2)：45.
[77]魏文清,赵满仓,刘晶,等.MTT肿瘤药物敏感试验的方法学研究,临床肿瘤学杂志,2008,13(10)：871-874
[78]秦婷婷,唐东平.MTT方法体外应用新进展,现代肿瘤医学,2008,16(10)：1835-1837
[79]杨芳,路国华.影响MTT实验比色的关键环节,第四军医大学学报,2009,30(3)：243
[80]邬于川,王元正,蒋英,等.MTT比色分析法的方法学讨论,泸州医学院学报,1996,19(3)：189-191
[81]丁岩,何丽容,曹卡加,等.叠氮甲基葸醌衍生物诱导KB细胞及其耐药株细胞的凋亡,药学学报,2005,40(1)：22-26
[82]De Wys W. Management of cancer cachexia[J]. Sem Oncol,1985,12:452-460.
[83]陈育尧,等.虻虫提取物对大鼠出血时间、纤维蛋白原含量及血小板聚集性的影响.第一军医大学学报,2000,10(3)：260～261.
[84]姚文兵,陈琼华.波叶大黄多糖对免疫功能的促进作用.中国药科大学学报,1999,21(2)：99.
[85]金静君,魏一生,何萍,等.MTT法对白血病细胞株化疗药物敏感性检测,海峡药学,1997,9(4)：51-52
[86]郭炜,赵泽贞,单保恩,等.六种中草药的抗突变及抗肿瘤活性的实验报告.癌变.畸变.突变,2002,14(2)：95-97.
[87]徐瑞成,陈小义,陈莉.Bafalin抗癌机制研究进展[J].国外医学·肿瘤学分册,2000,27(4)：201.
[88]吴丹勇,常兆生.来源于动物的抗肿瘤活性物质及其生物活性.中国药学杂志,1992,27(5)：265.
[89]周振华,宋振明,于尔辛,等.中药诱导肿瘤细胞凋亡的研究进展,国外医学.中医 中药分册,1998,(3)：3.
[90]李艳荣.蟾蜍毒素的抗肿瘤作用[J].国外医学中医中药分册,2002,24(3)：152.
[91]季宇彬.抗癌中药药理与应用.黑龙江：黑龙江科学技术出版社,2004,2：1076.
[92]汪艳,吴曙光,许伟,等.米糖多糖抗肿瘤作用及其作用的部分机制.中国药理学通报,1999,15(1)：70-72.
[93]华海清,王锦鸿,秦叔逵.砒霜古今应用探讨[J].中国中药杂志,2003,28(2)：186-188.
[94]周岱翰.临床中医肿瘤学.北京：人民卫生出版社,2003,1：416.
[95]邹益友,谭桂山.猕猴桃根抑制肿瘤细胞的实验研究[J].湖南中医药导报,1999,5(4)：37-38.
[96]张殿增,王美纳,邱培伦.大黄蟅虫丸对血淤证动物微循环的影响.西安医科大学学报,1994,15(1)：37.
[97]张国铎.活血化瘀法抗肿瘤机理的研究进展[J].浙江中医杂志,2002,37(4)：180.
[98]宋立人,洪恂,丁绪亮,等.现代中药学大辞典[M].北京：人民卫生出版社,2001.1-100.
[99]徐国钧,黄泰康,丁志遵,等.中药辞海(第二卷)[M].北京：中国医药科技出版社,1997.608.
[100]邹英杰.大黄的现代药理研究.中国医药卫生,2007,5(8)：81.
[101]朱建亮.桃仁提取液合人工虫草菌丝对肝炎后肝硬化免疫机能异常的调节作用.中国中西医结合杂志,1992,12(4)：207.
[102]程红霞,林强,程维明,等.苄基异哇琳类生物碱药理作用及机制的研究进展,中国新药与临床杂志,2006,25(5)：392-399
[103]Zamora JM, Pearce HL, and Beck WT. Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol Pharmacol.,1988.33(4):454-462.
[104]Chen Y, Pant AC, Simon SM. P-Glycoprotein does not reduce substrate concentration from the extracellular leaflet of the plasma membrane in living cells. Cancer Res.,2001,61(21):7763-7769.
[105]InuiA. Cancer anorexia-cachexia syndrone:current issues in resea-rch and management[J]. CA Cancer J clin,2002,52(2):72-91.
[106]李克明,张国,武继彪,等.水蛭的药理研究概况.中医研究,2007,20(2)：62-64.
[107]叶仙蓉,吴克美.三尖杉碱和桥氧三尖杉碱衍生物的合成及抗肿瘤活性,药学学报,2003,38(12)：919-923
[108]宋·唐慎微.重修政和经史证类本草.人民卫生出版社,1957：468.
[109]明·李时珍.本草纲目.人民卫生出版社：2285.
[110]涂玉堂.水蛭基原探索.时珍国医国药,2001,12(4)：348.
[111]宋金斌,周琴妹.对《中国药典》水蛭动物来源的商榷.时珍国药研究,1997,8(2)：104.
[112]肖小芹.水蛭原动物种类及活体鉴别.中药研究与信息,2000,2(7)：45;41.
[113]覃树先.水蛭与动物蚂蟥抗凝血作用的比较.广西中医学院学报,2000,17(3)：78-79.
[114]吴志军,张灵霞,于立华.四种不同品种水蛭生物活性的研究与比较,2006,28(2)：232-234.
[115]单书健,陈子华.古今名医临证金鉴[M]..北京：中国中医药出版社,2000：11-12.
[116]祝新年,马茹人.瘤瘕积聚专辑[M].上海：科学技术出版社,2003：5-5.
[117]王建国.张景岳治疗积聚思想初探[J].实用中西医结合临床,2004,4(5)77-78.
[118]刘立公,顾杰.癥瘕积聚的古代针灸治疗特点分析[J].针灸临床杂志,2004,20(2)：5-7.
[119]沈烈钧.隋唐医家痰饮积聚学术特点初探及临证举隅[J].上海中医药大学学报,2003：1-3.
[120]杨新中,熊裕家,罗秀丽.中西医结合治疗肿瘤的新观念[J].湖北中医杂志,2001,23(1)：3-4.
[121]胥彬·肿瘤药理学新论[M]·北京：人民卫生出版社,2004.471.
[122]陶旭辉,唐德才.活血化瘀药抗肿瘤血管生成研究述略[J].中医药学刊,2003,21(12),2085.
[123]汪红,王强,余国奠.近十年抗肿瘤中药的研究进展[J].中国野生植物资源,1999,19(3)：7-10.
[124]孙六合,曹健美.抗癌膏穴贴及内服中药对荷瘤小鼠脾LAK细胞活性和SIL-2R水平的影响[J].河南中医,2001,21(3)：15-17.
[125]曾元璋.10种有毒中草药抗肿瘤作用浅析[J].湖南中医药导报,1988,4(5)：8.
[126]赵培荣,田爱琴,马湘玲,等.山豆根对人食管癌细胞株(Eca-109)杀伤、抑制及脱氧氢酶类的影响[J],河南肿瘤学杂志,1998,11(2)：87-89.
[127]刘晨江,赵志鸿.冬凌草的研究进展[J].中国药学杂志,1998,33(10)：577-581.
[128]侯俊民,束永前,赵志泉.紫杉醇对人食管癌Eca109细胞株生长的影响[J].南京医科大学学报,2001,21(3)：235-238.
[2]闰洪飞.谈浅中医肿瘤病名的命名,中医文献杂志,2004, (4)：34
[3]郭炜,赵泽贞,单保恩,等.六种中草药的抗突变及抗肿瘤活性的实验报告.癌变.畸变.突变,2002,14(2)：95-97.
[4]赵泽贞,魏丽珍.22种可食性中药材的抗突变和致突变同步快速试验,癌变、畸变、突变,2002,12(2)：8789
[5]施汀兰,杨雪,冉长清.中药抗肿瘤作用研究概况,重庆中草药研究,2008(2)：32
[6]郑炜望,华海清.中药诱导肝癌细胞凋亡的研究进展.世界华人消化杂志2009；17(28)：2915-2918
[7]殳迎春,范平国.动物类中药在抗肿瘤方面的应用,现代医药卫生2005,21(20)：2820
[8]汪海英.抗肿瘤中药的研究现状,青海医学院学报,2008,29(4)：278
[9]郭娟娟,潘祥林,冯长伟,等.冬凌草甲素诱导多药耐药细胞系K562／A02凋亡、逆转耐药性的研究,安徽中医学院学报,2000,19(3)：34.
[10]马龙,徐臻荣,付德润,等.新疆红景天水提取液抗诱变作用的实验研究[J].现代康复,1998；2(1)：58-59.
[11]韩玉英,丰平,文朝阳.抗癌中草药研究进展,北京中医杂志,2003,22(2)：45
[12]肖秀玲,贾海波.中药有效成分抗肿瘤作用研究进展[J].内蒙古中医药,2007(5)：47.
[13]江石湖,徐水平,谭继宏,等.羟基喜树碱诱导胃癌细胞凋亡的实验研究.中华消化杂志,1999,19(1)：19-20.
[14]徐令,廖清奎,罗春化,等.Fas基因在高三尖杉酯碱诱导HL-60细胞凋亡中的作用. 中华儿科杂志,1998,10(10)：607-609.
[15]周振华,宋振明,于尔辛,等.中药诱导肿瘤细胞凋亡的研究进展,国外医学.中医中药分册,1998,(3)：3.
[16]杨小萍,潘启超,谢冰芬,等.骆驼蓬总碱抗肿瘤及其协同抗瘤作用[J].中草药,1998,29(9)：609—611.
[17]黄园,庄镇华,侯世祥,等.草乌抗肝癌靶向制剂有效部位的浸出、纯化与确认[J].中国中药杂志,1997,22(11)：667—671.
[18]咸丽娜,钱士辉,抗癌中药研究进展,中国野生植物资源,2009,28(4)：1
[19]许继平,周振鹤,杨锋,等.六味地黄液抗肿瘤化疗的毒副作用研究.中国中西医结合杂志,1992,15(12)：734
[20]邢雪梅,邢聪,邢磊,等.抗癌中药的生物治疗效应研究近况.中医杂志,1994,35(3)：177.
[21]贺新怀,席孝贤.试论中药诱导肿瘤细胞凋亡的机制[J].陕西中医学院学报,1999,22(5)： 62.
[22]王明艳,吴海涛,赵鸣芳,等.4种方药对环磷酰胺诱发的SCE的抑制作用[J].中成药药,2000,22(3)：212-214
[23]李震,李军山,李哲,等.清热解毒方对肿瘤小鼠红细胞膜流动性及血浆环核苷酸水平的影响,山东生物医学工程,2001,20(3)：8
[24]陈培丰.清热解毒法诱导肿瘤细胞凋亡的研究,浙江中医学院学报2003,27(1)：12
[25]原志庆.6种中草药阻断食管上皮癌变的实验研究.河南肿瘤学杂志,1998,11(5)：396-397.
[26]金红,吴湘玮,潘博,等.鼻咽复方配合放疗治疗鼻咽癌260例疗效观察.湖南中医杂志,1997,13(3)：20.
[27]陈英.益气养血、清热解毒治疗乳癌术后41例,浙江中医学院学报,1999,23(6)：30.
[28]贾英杰,田菲,陈军,等.解毒祛瘀法对肿瘤血管生成影响的实验研究[J].天津中医药,2004,21(6)：467-469.
[29]曹科,潘艳芳,陈佩禅,等.抵当汤对小鼠肿瘤转移及酪氨酸激酶受体信号传导系统EGFR的影响[J].中医药学刊,2004,22(11)：2026.
[30]吴焱森,谢则平.抵当汤对荷瘤小鼠免疫功能影响的实验研究[J].湖北省卫生职工医学院学报,2001,14(2)；6.
[31]许洪霞,王雅贤,许艳霞.桃核承气汤对荷瘤小鼠影响的实验研究[J].中医药信息,2006,23(1)：52.
[32]王学良,杨运高,王程.抵当汤抑制肿瘤转移的实验研究,湖南中医杂志2004,(20)3：69
[33]韩彦龙.桂枝茯苓丸抗肿瘤作用的实验研究,牡丹江医学院学报,2003,24(6)：9
[34]陈泽雄,陈雯,彭俊生,等.中药复方抗癌方抑制人结肠癌细胞株端粒酶活性.中国胃肠外科杂志,1999,2(2)：117-118.
[35]邬晓东.自拟鳖陈汤治疗恶性肿瘤验案3则,成都中医药大学学报,2002,25(2)：46-47.
[36]夏亲华.中药扶正培本、化瘀解毒配合腹腔化疗治疗晚期卵巢癌.安徽中医临床杂志,1999,11(1)：5-6.
[37]杨振江,赵霞.髓清丸对裸小鼠黑色素瘤B16自发性肺转移影响的研究[J].成都中医药大学学报,2004,27(2)：30-32.
[38]李学汤,王永泉,傅乃武.几种活血化瘀药物对小鼠肝癌细胞形成肺转移影响的初步实验观察[J].中医杂志,1980,21(8)：75.
[39]傅乃武,范贤俊,王永泉,等.丹参对实验肿瘤生长和转移的影响及其作用原理的初步探讨[J].中华肿瘤杂志,1981,3(3)：165.
[40]黄兆明,何小琴.丹参、赤芍、莪术对小鼠Lewis肺癌血管生成的影响[J].实用中西医结合临床,2006,6(1)：74-75.
[41]毕良研,杨秀婷,姜家康,等.活血化瘀法不宜应用于恶性肿瘤的临床治疗[J].中医药学报,1997(2)：
[42]徐德成,张培宇.活血化瘀强度与气血双亏型胃癌转移率相关性机制探讨[J]中医杂志,1998,39(3)：156.
[43]夏跃胜,王建华,刘星,等.放射疗法联合应用活血与扶正活血中药治疗鼻咽癌的对比研究[J].中国中西医结合耳鼻咽喉科杂志,2002,10(2)：72.
[44]陈刚,徐晓玉,严鹏科,等.川芎嗪和丹参对小鼠Lewis肺癌生长的抑制作用与抑制血管生成的关系[J].中草药,2004,35(3)：296-299.
[45]刘明章,黄胎核,肖伟瑶.丹参酮ⅡA磺酸钠对Lewis肺癌无促进生长与转移作用[J].中国药理学报,1991,12(6)：534.
[46]张海林,聂克.活血化瘀药对恶性肿瘤影响研究进展,山东中医药大学学报,2009,32(2)：169
[47]周仲瑛.瘀热相搏证的系列研究(一).天津中医药大学学报,2008,27(3)：151
[48]周仲瑛.瘀热相搏证的系列研究(二).天津中医药大学学报,2008,27(4)：237
[49]张静,吴正.凉血散淤抗肿瘤研究进展,时珍国医国药2008,(19)4：1017
[50]陈宁.中晚期原发性肝癌中药应用规律[J].陕西中医,1995,16(2)：87.
[51]吴勉华,过伟峰,周学平,等.研究周仲瑛“瘀热”学说的思路与方法,中华中医药杂志,2009,24(10)：1319
[52]吴贻谷,宋立人.《中华本草》.上海科学技术出版社,1999
[53]刘敏,刘振权,李宇航,等.仲景方中水蛭用药剂量研究,中国现代药物应用,2009,21(3)：77
[54]活血祛瘀剂选药配伍规律纵横谈,2002年山东中医药大学硕士研究生论文
[55]罗眈,陈名斌,彭睿,等.活血化瘀配伍方法探析,四川中医,2008,26(11)：105
[56]姜波,艾华.抵当汤化裁方对荷瘤小鼠抑瘤作用及对T淋巴细胞亚群的影响,吉林中医药2008,(28)2：147
[57]吴焱森,抵当汤对荷瘤小鼠免疫功能影响的实验研究,湖北省卫生职工医学院学报2001,(14)2：6
[58]杨运高,王程,王学良,等.红细胞免疫低下与肿瘤转移及活血化瘀方药的调节,湖南中医杂志,2004,20(6)：52
[59]王学良,杨运高,王程.抵当汤抑制肿瘤转移的实验研究,2004,20(3)：69
[60]王程,杨运高,王学良.活血化瘀经典方剂对小鼠大肠癌肝转移模型端粒酶及p53、C-erbB-2、Bcl-2基因表达的影响[J].第一军医大学学报,2004,24(7)：11.
[61]刘京生,苗智慧,董力,等.水蛭抗肿瘤作用的实验研究[J].时珍国医国药,2001,12(10)：884-885
[62]谢艳华,王四旺,崔翰明.水蛭对正常及血瘀模型大鼠血液流变的影响[J].第四军医大学学报,1996,17(2)：52.
[63]黄国钧,王选明,毛兴云,等.回生口服液抗肿瘤作用实验研究.中成药,1998,20(10)：37～39.
[64]难波恒雄.生药学杂志(日),1982,36(4)：289
[65]沈映君.中药药理学[M].上海：上海科学技术出版社,1997
[66]万宗明,孙文军,陈虹.大黄酸抗肿瘤作用的研究进展.武警医学杂志,2006,17(8)：611.
[67]孙丽霞,任金荣,单保恩,等.大黄制剂对小鼠的急性毒性和自然免疫调节作用.癌变·畸变·突变,2006,18(1)：35.
[68]刘英,张伟刚,王雅贤,等.炒桃仁总蛋白对小鼠B细胞功能影响的实验研究.中医药学报,2001,29(2)：55.
[69]吕跃山,王雅贤,运晨霞,等.桃仁总蛋白对荷瘤鼠IL-2、IL-4水平的影响,中医药信息,2004,21(4)：60
[70]杨雁,陈敏珠.黄芪总苷对肝癌细胞凋亡及wtp53基因表达的影响.中国药理学通报2001； 17：447-451
[71]金宏勋.黄芪水煎液对环磷酞胺抗肿瘤活性与毒性的影响.中药材,1995,18(7)：356.
[72]马占好.黄芪多糖对小鼠提内六种细胞系瘤株抑瘤作用的实验研究[J].中医药学报,1996(4)：55-56.
[73]季宇彬.抗癌中药药理与应用.黑龙江：黑龙江科学技术出版社,2004,2：1075.
[74]黄敬群,罗晓星,王四旺,等.桂皮醛抗肿瘤活性及对S180荷瘤小鼠免疫功能的影 响[J].中国临床康复.2006,10(11)：107-110.
[75]和水祥,罗金燕,赵刚,等.柴胡皂苷对肝癌SMMC-7721细胞环氧合酶-2表达的影响[J].中华肝脏病杂志,2006,14(9)：712-714.
[76]韩玉英,丰平,文朝阳.抗癌中草药研究进展[J].北京中医杂志,2003,22(2)：45.
[77]魏文清,赵满仓,刘晶,等.MTT肿瘤药物敏感试验的方法学研究,临床肿瘤学杂志,2008,13(10)：871-874
[78]秦婷婷,唐东平.MTT方法体外应用新进展,现代肿瘤医学,2008,16(10)：1835-1837
[79]杨芳,路国华.影响MTT实验比色的关键环节,第四军医大学学报,2009,30(3)：243
[80]邬于川,王元正,蒋英,等.MTT比色分析法的方法学讨论,泸州医学院学报,1996,19(3)：189-191
[81]丁岩,何丽容,曹卡加,等.叠氮甲基葸醌衍生物诱导KB细胞及其耐药株细胞的凋亡,药学学报,2005,40(1)：22-26
[82]De Wys W. Management of cancer cachexia[J]. Sem Oncol,1985,12:452-460.
[83]陈育尧,等.虻虫提取物对大鼠出血时间、纤维蛋白原含量及血小板聚集性的影响.第一军医大学学报,2000,10(3)：260～261.
[84]姚文兵,陈琼华.波叶大黄多糖对免疫功能的促进作用.中国药科大学学报,1999,21(2)：99.
[85]金静君,魏一生,何萍,等.MTT法对白血病细胞株化疗药物敏感性检测,海峡药学,1997,9(4)：51-52
[86]郭炜,赵泽贞,单保恩,等.六种中草药的抗突变及抗肿瘤活性的实验报告.癌变.畸变.突变,2002,14(2)：95-97.
[87]徐瑞成,陈小义,陈莉.Bafalin抗癌机制研究进展[J].国外医学·肿瘤学分册,2000,27(4)：201.
[88]吴丹勇,常兆生.来源于动物的抗肿瘤活性物质及其生物活性.中国药学杂志,1992,27(5)：265.
[89]周振华,宋振明,于尔辛,等.中药诱导肿瘤细胞凋亡的研究进展,国外医学.中医 中药分册,1998,(3)：3.
[90]李艳荣.蟾蜍毒素的抗肿瘤作用[J].国外医学中医中药分册,2002,24(3)：152.
[91]季宇彬.抗癌中药药理与应用.黑龙江：黑龙江科学技术出版社,2004,2：1076.
[92]汪艳,吴曙光,许伟,等.米糖多糖抗肿瘤作用及其作用的部分机制.中国药理学通报,1999,15(1)：70-72.
[93]华海清,王锦鸿,秦叔逵.砒霜古今应用探讨[J].中国中药杂志,2003,28(2)：186-188.
[94]周岱翰.临床中医肿瘤学.北京：人民卫生出版社,2003,1：416.
[95]邹益友,谭桂山.猕猴桃根抑制肿瘤细胞的实验研究[J].湖南中医药导报,1999,5(4)：37-38.
[96]张殿增,王美纳,邱培伦.大黄蟅虫丸对血淤证动物微循环的影响.西安医科大学学报,1994,15(1)：37.
[97]张国铎.活血化瘀法抗肿瘤机理的研究进展[J].浙江中医杂志,2002,37(4)：180.
[98]宋立人,洪恂,丁绪亮,等.现代中药学大辞典[M].北京：人民卫生出版社,2001.1-100.
[99]徐国钧,黄泰康,丁志遵,等.中药辞海(第二卷)[M].北京：中国医药科技出版社,1997.608.
[100]邹英杰.大黄的现代药理研究.中国医药卫生,2007,5(8)：81.
[101]朱建亮.桃仁提取液合人工虫草菌丝对肝炎后肝硬化免疫机能异常的调节作用.中国中西医结合杂志,1992,12(4)：207.
[102]程红霞,林强,程维明,等.苄基异哇琳类生物碱药理作用及机制的研究进展,中国新药与临床杂志,2006,25(5)：392-399
[103]Zamora JM, Pearce HL, and Beck WT. Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol Pharmacol.,1988.33(4):454-462.
[104]Chen Y, Pant AC, Simon SM. P-Glycoprotein does not reduce substrate concentration from the extracellular leaflet of the plasma membrane in living cells. Cancer Res.,2001,61(21):7763-7769.
[105]InuiA. Cancer anorexia-cachexia syndrone:current issues in resea-rch and management[J]. CA Cancer J clin,2002,52(2):72-91.
[106]李克明,张国,武继彪,等.水蛭的药理研究概况.中医研究,2007,20(2)：62-64.
[107]叶仙蓉,吴克美.三尖杉碱和桥氧三尖杉碱衍生物的合成及抗肿瘤活性,药学学报,2003,38(12)：919-923
[108]宋·唐慎微.重修政和经史证类本草.人民卫生出版社,1957：468.
[109]明·李时珍.本草纲目.人民卫生出版社：2285.
[110]涂玉堂.水蛭基原探索.时珍国医国药,2001,12(4)：348.
[111]宋金斌,周琴妹.对《中国药典》水蛭动物来源的商榷.时珍国药研究,1997,8(2)：104.
[112]肖小芹.水蛭原动物种类及活体鉴别.中药研究与信息,2000,2(7)：45;41.
[113]覃树先.水蛭与动物蚂蟥抗凝血作用的比较.广西中医学院学报,2000,17(3)：78-79.
[114]吴志军,张灵霞,于立华.四种不同品种水蛭生物活性的研究与比较,2006,28(2)：232-234.
[115]单书健,陈子华.古今名医临证金鉴[M]..北京：中国中医药出版社,2000：11-12.
[116]祝新年,马茹人.瘤瘕积聚专辑[M].上海：科学技术出版社,2003：5-5.
[117]王建国.张景岳治疗积聚思想初探[J].实用中西医结合临床,2004,4(5)77-78.
[118]刘立公,顾杰.癥瘕积聚的古代针灸治疗特点分析[J].针灸临床杂志,2004,20(2)：5-7.
[119]沈烈钧.隋唐医家痰饮积聚学术特点初探及临证举隅[J].上海中医药大学学报,2003：1-3.
[120]杨新中,熊裕家,罗秀丽.中西医结合治疗肿瘤的新观念[J].湖北中医杂志,2001,23(1)：3-4.
[121]胥彬·肿瘤药理学新论[M]·北京：人民卫生出版社,2004.471.
[122]陶旭辉,唐德才.活血化瘀药抗肿瘤血管生成研究述略[J].中医药学刊,2003,21(12),2085.
[123]汪红,王强,余国奠.近十年抗肿瘤中药的研究进展[J].中国野生植物资源,1999,19(3)：7-10.
[124]孙六合,曹健美.抗癌膏穴贴及内服中药对荷瘤小鼠脾LAK细胞活性和SIL-2R水平的影响[J].河南中医,2001,21(3)：15-17.
[125]曾元璋.10种有毒中草药抗肿瘤作用浅析[J].湖南中医药导报,1988,4(5)：8.
[126]赵培荣,田爱琴,马湘玲,等.山豆根对人食管癌细胞株(Eca-109)杀伤、抑制及脱氧氢酶类的影响[J],河南肿瘤学杂志,1998,11(2)：87-89.
[127]刘晨江,赵志鸿.冬凌草的研究进展[J].中国药学杂志,1998,33(10)：577-581.
[128]侯俊民,束永前,赵志泉.紫杉醇对人食管癌Eca109细胞株生长的影响[J].南京医科大学学报,2001,21(3)：235-238.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |